Abstract Fanconi anemia (FA), an autosomal recessive disorder characterized by a progressive pancytopenia associated with congenital anomalies and high predisposition to malignancies, is a genetically and clinically heterogeneous disease. At least eight complementation groups (FA-A to FA-H) have been identified. Previously, we studied mutations of the FANCA gene, responsible for FA-A, and found pathogenic mutations in 12 of 15 unclassified Japanese FA patients. Here, we further studied an additional 5 FA patients for sequence alterations of the FANCA gene and found pathogenic mutations in 2 of them. We further analyzed mutations of the FANCC and FANCG genes, responsible for FA-C and FA-G, respectively, in the remaining 6 FA patients. Although there was no alterations in the FANCC gene in these 6 patients, two novel mutations of the FANCG gene, causing aberrant RNA splicing, were detected in 2 FA patients. One was a base substitution from G to C of the invariant GT dinucleotides at the splice donor site of intron 3, resulting in the skipping of exon 3, as well as the skipping of exons 3 and 4. The other was a base substitution from C to T in exon 8, creating a nonsense codon (Q356X). This mutation resulted in the exclusion of a sequence of 18 nucleotides containing the mutation from the mRNA, without affecting the splicing potential of either the authentic or the cryptic splice donor site. Collectively, 14 of the 20 unclassified Japanese FA patients belong to the FA-A group, 2 belong to the FA-G group, and none belongs to the FA-C group.
Introduction
Fanconi anemia (FA) is a rare autosomal recessive disease characterized by a progressive pancytopenia to aplasia, often associated with congenital anomalies and a markedly increased predisposition to leukemia and other cancers (Butturini et al. 1994) . FA is genetically and clinically heterogeneous, but hypersensitivity to cell killing and the formation of chromosome aberrations by DNA cross-linking agents, such as mitomycin C (MMC), have been a hallmark of the disease (Sasaki 1975; Sasaki 1978; Sasaki and Tonomura 1973) . To date, at least eight complementation groups (A to H) have been identified by somatic cell hybridization and genetic linkage studies (Joenje et al. 1995; Joenje et al. 1997; Mann et al. 1991; Savoia et al. 1996; Strathdee et al. 1992a) , with the relative prevalence varying among ethnic groups (Jakobs et al. 1997; Joenje 1996; Savoia et al. 1996) . The genes for three complementation groups, FANCA (OMIM no. 227650) for group A, FANCC (OMIM no. 227645) for group C, and FANCG (OMIM no. 602956) for group G, have been identified (de Winter et al. 1998 ; The Fanconi anaemia/breast cancer consortium 1996; Lo Ten Foe et al. 1996; Strathdee et al. 1992b) . They are orphan genes, being unrelated to each other or to other known genes. The functions of the gene products are largely unknown, but it is suggested that they are functionally related because their mutations display a similar phenotype. Current studies reveal that, while they localize predominantly in the cytoplasm, FANCA and FANCC proteins form a complex and co-localize in the nucleus, suggesting interrelation in a nuclear function (Kupfer et al. 1997) . The FANCG gene isolated by functional complementation of an FA-G cell line (de Winter et al. 1998 ) was found to be identical to the human XRCC9 gene, which had been isolated as a gene that complemented the MMC-sensitive Chinese hamster mutant UV40 (Liu et al. 1997) . It has been reported that FANCG protein also forms a large nuclear complex with FANCA and FANCC proteins (GarciaHiguera et al. 1999 ).
The identification of responsible genes enables one to assign FA patients to complementation groups A, C, and G by direct mutation analysis. In a consecutive analysis in 15 unclassified Japanese FA patients for mutations of the FANCA gene, we found that 12 harbored the pathogenic mutations, indicating a predominance of group A patients in the Japanese population, while the remainder of the patients were not characterized (Tachibana et al. 1999) . Here, we further extended the mutation analysis of the FANCA gene in an additional 5 patients and then tested for mutation of the FANCC and FANCG genes in the patients who did not show mutations of the FANCA gene, including those in the previous patients panel. Collectively, 14 of the 20 Japanese FA patients revealed disease-associated mutations of the FANCA gene; 2 had mutations of the FANCG gene, and none had mutations of the FANCC gene. Mutations of the FANCG gene are novel mutations that affect RNA splicing and add to the four mutations so far identified in non-Japanese patients.
Materials and methods

Patients and cell cultures
The patients belong to a series of patients who were clinically suspected of having FA, with the disease confirmed by chromosome sensitivity to MMC. Fifteen of the patients were previously examined for mutations of the FANCA gene (Tachibana et al. 1999 ). The present study included an additional 5 patients. Fibroblast cultures, initiated from skin biopsies, using α-modified minimum essential medium (Irvine Scientific, Santa Ana, CA, USA) supplemented with 10% fetal bovine serum, were used for mutation analysis in their early passages.
Polymerase chain reaction (PCR) and sequencing
Reverse transcriptase-polymerase chain reaction (RT-PCR) and PCR of genomic DNA were performed as described previously, with slight modifications (Tachibana et al. 1999) . Briefly, poly(A) ϩ RNA and genomic DNA were isolated from cultured skin fibroblasts using TRIzol reagent (Gibco BRL, Rockville, MD, USA), and the first-strand cDNA was synthesized using a Superscript Kit (Gibco BRL). The firststrand cDNA was amplified by PCR, using the GeneAmp XL PCR Kit (Perkin-Elmer, Norwalk, CT, USA). Primers for PCR and sequencing were designed according to the published nucleotide sequence of the FANCC and FANCG cDNAs and the FANCG genomic DNA ( Table 1 ). The FANCG exons 3 and 8, and their flanking regions, were amplified using AmpliTaq (Perkin-Elmer) with primers FANCGex3pF and FANCGex3pR, and FANCGex8pF and FANCGex8pR, respectively. The genomic region from exons 1 to 7 of the FANCG gene was amplified with primers FANCGpF1 and FANCGpR3, using the GeneAmp XL PCR Kit. For subcloning of PCR products of cDNA, the TOPO XL PCR Cloning Kit (Invitrogen, Carlsbad, CA, USA) was used, following the manufacturer's instructions.
Reactions for sequencing of the PCR products and plasmid clones were performed using a BigDye Terminator Kit (Perkin-Elmer) in both directions. The sequencing reaction products were analyzed on an automated sequencer Genetic Analyzer ABI310 (Perkin-Elmer).
Restriction fragment length polymorphism analysis
Restriction fragment length polymorphism (RFLP) analysis was performed for exon 3 of the FANCG gene, using the restriction enzyme, DdeI, purchased from Toyobo (Osaka, Japan). The PCR product of exon 3 of the FANCG gene was digested with DdeI under the reaction conditions recommended by the manufacturer, and subjected to 12% polyacrylamide gel electrophoresis, followed by ethidium bromide staining.
Calculation of the splice site score
The splice site score was calculated following the formulas described by Shapiro and Senapathy (1987) , using the tabulated nucleotide frequencies (Senapathy et al. 1990 ).
Results
Mutation analysis of the FANCA gene
We previously reported mutations of the FANCA gene in 12 of 15 unclassified Japanese FA patients (Tachibana et al. 1999) . Here, we further analyzed the mutations of the FANCA gene in an additional 5 FA patients, and found pathogenic mutations in 2 patients, AP63P and AP68P (Table 2 ). AP68P was compound heterozygous for mutations 1303CϾT and 2546delC, both of which have been found in Japanese patients in our previous study (Tachibana et al. 1999) . AP63P was heterozygous for 2546delC and 3245TϾC. The latter is a new mutation (which has not been reported previously) causing an amino acid substitution of proline for leucine at codon 1083 (L1083P). Because there is no restriction site suitable for RFLP analysis at this site, we sequenced this region in ten unrelated control individuals, and found no alteration (data not shown). It is not conclusive whether this mutation is pathogenic, but it is likely to be related to the disease, as this is the sole mutation which could be relevant to the disease, except for 2546delC, in this patient, and it is not present in the other 39 alleles in the present FA panel. Together with the results of our previous study, pathogenic mutations of the FANCA gene were found in 14 of 20 unclassified Japanese FA patients.
Mutation analysis of the FANCC gene
The mutation analysis of the FANCA gene revealed that six patients, ie., AP02P, AP25B, AP37P, AP54B, AP65P, and AP66P, were not assigned to FA-A. We next analyzed mutation in the FANCC gene in these non-FA-A patients, using RT-PCR and direct sequencing of the FANCC cDNA. No sequence alteration was detected in the FANCC gene in any of these patients (data not shown).
Mutations of the FANCG gene
Next, we analyzed the FANCG gene in these six FA patients who were free of mutation of the FANCA and FANCC genes. The FANCG cDNA was amplified as a 2-kb fragment. Gel electrophoresis analysis of the PCR products revealed amplified products in all patients. Two of them, AP02P and AP66P, showed two smaller bands, of 1.9-kb and 1.7-kb, respectively, indicating the presence of se- 
FA, Fanconi anemia a Relative susceptibility to chromosome breakage by mitomycin C (MMC) as compared with control children b Presence (ϩ) or absence (Ϫ) of the indicated mutation c Disease-associated pathogenic mutations. The presence is market by boldface for each patient quence alterations in the cDNA (Fig. 1) . The other patients showed bands of normal size. Direct sequencing of the RT-PCR products revealed sequence alterations in cDNA in two patients, AP02P and AP66P, but no sequence alteration in the other four patients (Table 3) . RT-PCR analysis showed that AP66P had two cDNA species; both were shorter than the normal band, and there was no band of normal size (Fig. 1) . Direct sequencing of cDNA showed that these two small bands corresponded to the skipping of exon 3 (176-307del) and the skipping of exons 3 and 4 (176-510del), respectively ( Fig.  2A) . Cloning and sequencing of the RT-PCR products of AP66P confirmed these two alterations (Fig. 2B) . The ratio of the 176-307del clones to the 176-510del clones was 9 to 11. The region of genomic DNA from exon 1 to exon 7 of AP66P was sequenced, and one homozygous base substitution was detected at the splice donor site of intron 3 (IVS3ϩ1GϾC) (Fig. 2C) . The family members of AP66P were also analyzed. RT-PCR analysis detected normal size and two smaller bands in both the father (AP66F) and the mother (AP66M), but only the normal size band in the sister of the patient (AP66S) (Fig. 1) . Sequence analysis of the cDNA showed that both AP66F and AP66M had normal cDNA and two altered cDNAs, of 176-307del and 176-510del, respectively, while AP66S showed no alteration ( Fig. 2A) . Genomic DNA sequence revealed that both AP66F and AP66M were heterozygous for IVS3ϩ1GϾC (Fig. 2C) . The deletion 176-307del in cDNA removes entire exon 3, deleting 132 bp, resulting in an in-frame deletion of 44 amino acids. The deletion 176-510del removes both exon 3 and exon 4, deleting 335 bp, which yields an out-of-frame mRNA with a termination codon TAA at new codon 63. Neither RT-PCR gel electrophoresis patterns nor sequencing profiles showed any trace amounts of alternatively spliced products in normal control individuals (as shown in Figs. 1 and 2A) . As IVS3ϩ1GϾC creates a new restriction site of DdeI, RFLP analysis was performed in 20 non-FA controls. No alteration was identified in control individuals, suggesting that this base substitution is not a polymorphism (data not shown). AP02P also showed two short RT-PCR bands and an apparently normal size band. Sequence analysis revealed that the two short bands were 176-307del and 176-510del, respectively. Genomic DNA analysis showed that this patient was heterozygous for IVS3ϩ1GϾC. Another sequence alteration in AP02P cDNA was 1059-1076del, removing 18 nucleotides from the end of exon 8 (Fig. 3A) .
This alteration resulted in a deletion of six amino acids in the FANCG gene product. Sequence analysis of genomic DNA showed a heterozygous CϾT substitution at position ϩ142 in exon 8 (1066CϾT) (Fig. 3B) . The corresponding amino acid alteration was a substitution of a termination codon (X) for glutamine (Q) at codon 356 (Q356X) in the characterized coding sequence for FANCG. This base substitution was located at 11 bp upstream from the end of exon 8, and was not present in the cDNA, as the sequence containing this mutation was spliced out from the mRNA. Family analysis showed that the mother of the patient (AP02M) had 176-307del and 176-510del in cDNA and was heterozy- The splice site score for the authentic splice donor site is indicated with the normal allele, and that for the cryptic splice donor site is indicated with the mutant allele. Brackets show 8 nucleotides used for calculation of the splice site scores gous for IVS3ϩ1GϾC, while the father (AP02F) had 1059-1076del in cDNA and was heterozygous for 1066CϾT in genomic DNA (Fig. 3A,B) . No sequence alteration was found in the genomic FANCG exon 8 of the 20 unrelated control individuals (data not shown), suggesting that this base substitution is not a polymorphism.
Discussion
We previously reported that pathogenic mutations of the FANCA gene were identified in 12 of 15 unclassified Japanese FA patients (Tachibana et al. 1999) . In this study, we further examined the FANCA gene in an additional 5 FA patients, and found pathogenic mutations in 2 patients. Both patients retained a frameshift mutation 2546delC. Collectively, the 2546delC mutation was observed in 8 of the 20 patients, confirming the most common mutation in Japanese FA patients. All together, we have analyzed the FANCA gene in 20 unrelated Japanese FA patients, and found pathogenic mutations in 14 of them (70%).
It has been reported that, in 13% of FA patients of European and United States/Canadian origin, the disease is due to mutations in the FANCC gene (Buchwald 1995) . However, we did not detect any sequence alteration in the FANCC gene in six non-FA-A patients. Due to the limitations of the RT-PCR method, we may have overlooked genetic changes causing loss of transcripts, such as large deletions and promoter mutations. However, we detected at least one normal FANCC cDNA in all patients, indicating that these patients do not belong to the FA-C group, because of the recessive nature of FA. In our separate experiments using the PCR-SSCP method in a panel of 20 other Japanese FA patients, we did not detect any mutations of the FANCC gene, except for a polymorphic variant AϾC transversion at 29 bp upstream from the initiation codon in exon 1 in two families (data not shown). All these observations indicate that FA-C patients are very rare (Ͻ1.8%, with a 95% confidence limit), if there are any at all, in the Japanese population, showing a clear ethnic difference from European and United States/Canadian populations.
We further examined the FANCG gene in 6 non-FA-A (and non-FA-C as well) patients, and found 2 novel mutations in 2 patients. Therefore, these 2 patients were assigned to FA-G. This indicates that 2 of 20 Japanese FA patients (10%) belong to the complementation group G. Although the number of patients examined is limited, FA-G patients are assumed to constitute a significant proportion of Japanese FA patients. No unique clinical features were found in these patients compared with the other FA patients. Both patients had short stature and café-au-lait spots, features which were common to the other FA patients, and they were not distinguishable from the other FA patients in their blood subtypes and cellularity in bone marrow. Furthermore, cells from both patients showed MMC sensitivity comparable to that of FA-A cells, as the MMC indexes for AP02P and AP66P were 53.9 (Tachibana et al. 1999 ) and 71.1 (Table 2) , respectively, indicating the uniformity of cellular phenotype among FA complementation groups.
One mutation identified in the FANCG gene was IVS3ϩ1GϾC, which provoked two alternatively spliced RNAs, that is, 176-307del and 176-510del. This mutation affected the splice donor site sequence in intron 3, and decreased the splice site score from 93.5 to 75.3 (Fig. 2D) . As the most common result of a mutation at the splice donor site is the skipping of the immediate upstream exon (Maquat 1996) , the skipping of exon 3 is the most probable consequence of this mutation. Mutations at the splice donor site which cause the skipping of multiple exons have been reported in only a few cases (Aoshima et al. 1996; Hayashida et al. 1994; Steingrimsdottir et al. 1992 ). In the FANCG gene, the splice site score at the donor site of intron 4 is relatively low (80.0), and this may be responsible for the coordinated skipping of exon 4 with exon 3.
Another mutation detected in the FANCG gene was 1066CϾT. This alteration could create premature termination of translation at codon 356 (Q356X). However, sequence analysis of the cDNA revealed a deletion of 18 nucleotides of exon 8 (1059-1076del), resulting in the inframe deletion of six codons. Thus, the CϾT mutation at 1066 resulted in the utilization of the cryptic splice donor site at 8 nucleotides upstream, although the splice site scores at both the cryptic site (71.5) and the authentic site (93.5) were not altered by this base substitution (Fig. 3C) . It has been reported that some of the nonsense-associated mutations cause splicing alterations, resulting in mRNA that either lacks the nonsense codon or circumvents the nonsense-generating frameshift mutation so as to terminate translation at or near the normal termination codon (Maquat 1996) . For instance, a nonsense mutation in exon 6 of the FANCC gene results in the skipping of exon 6 of 165 bp, causing an in-frame deletion in the FANCC gene product (Gibson et al. 1993) . Most of the cases reported so far show that the nonsense-associated mutation caused the skipping of the entire exon which contained the mutation. The mutation 1066CϾT is intriguing, as the nonsense mutation resulted in the skipping of part of an exon sequence, utilizing the cryptic splice donor site near the nonsense codon. It has been suggested that the mRNA molecules with a nonsense mutation are relatively unstable. Thus minor, alternatively spliced, mRNA species would become detectable (Maquat 1996) . Another mechanism is proposed, that nonsense codons can directly alter splice site selection (Dietz et al. 1993) . Further study of these two mutations in the FANCG gene would provide us with better understanding of the mechanism of RNA splicing.
Knowing the relative prevalence of FA subtypes and the pathogenic mutations in human populations is of great importance for the diagnosis of FA patients. The present study indicates that FA-A is predominant, and that FA-G constitutes a significant proportion of Japanese FA patients, but that FA-C is very rare in the Japanese population. In particular, 2546delC is the mutation of the FANCA gene appearing most frequently in Japanese FA patients, and it has not yet been identified in other ethnic groups. These ethnic characteristics should be useful for the ultimate diagnosis of Japanese FA patients.
